An Evaluation of Factors Affecting Antimalarial Drug Quality
Last registered on February 04, 2016

Pre-Trial

Trial Information
General Information
Title
An Evaluation of Factors Affecting Antimalarial Drug Quality
RCT ID
AEARCTR-0001033
Initial registration date
February 04, 2016
Last updated
February 04, 2016 5:45 PM EST
Location(s)
Region
Primary Investigator
Affiliation
University of Massachusetts, Boston
Other Primary Investigator(s)
Additional Trial Information
Status
Completed
Start date
2013-05-17
End date
2013-12-01
Secondary IDs
Abstract
In partnership with researchers at the Mbarara University of Science and Technology, I conduct an audit study to test whether improved customer information about healthcare purchases lowers prices or changes quality. I send pairs of mystery shoppers to private sector drug outlets in Uganda to purchase antimalarial drugs according to randomized scripts. The scripts experimentally vary information about the patient's diagnosis (malaria) and/or about appropriate treatment (artemether-lumefantrine). All purchases are tested using spectrometer to determine whether they are substandard. That data are linked with additional survey data of vendors and real customers.
External Link(s)
Registration Citation
Citation
Fitzpatrick, Anne. 2016. "An Evaluation of Factors Affecting Antimalarial Drug Quality." AEA RCT Registry. February 04. https://doi.org/10.1257/rct.1033-1.0.
Former Citation
Fitzpatrick, Anne. 2016. "An Evaluation of Factors Affecting Antimalarial Drug Quality." AEA RCT Registry. February 04. http://www.socialscienceregistry.org/trials/1033/history/6746.
Experimental Details
Interventions
Intervention(s)
Mystery shoppers purchase antimalarial drugs according to randomly assigned scripts. Scripts vary in knowledge of the patient's diagnosis (malaria) and/or appropriate treatment (artemether-lumefantrine, or AL). Data are then collected on the price and quality of the resulting transaction.
Intervention Start Date
2013-05-17
Intervention End Date
2013-12-01
Primary Outcomes
Primary Outcomes (end points)
Type of drug purchased; price; quality
Primary Outcomes (explanation)
Secondary Outcomes
Secondary Outcomes (end points)
Secondary Outcomes (explanation)
Experimental Design
Experimental Design
Mystery shoppers purchase antimalarial drugs according to randomly assigned scripts. Scripts vary in knowledge of the patient's diagnosis (malaria) and/or appropriate treatment (artemether-lumefantrine, or AL). Data are then collected on the price and quality of the resulting transaction.
Experimental Design Details
Randomization Method
Randomization was stratified by parish and implemented using Stata software.
Randomization Unit
Unit of randomization was a drug outlet.
Was the treatment clustered?
Yes
Experiment Characteristics
Sample size: planned number of clusters
538 outlets
Sample size: planned number of observations
933 purchases from these outlets
Sample size (or number of clusters) by treatment arms
Sample was divided approximately evenly among the 4 treatment groups.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
Used optimal design software.
IRB
INSTITUTIONAL REVIEW BOARDS (IRBs)
IRB Name
Mbarara University of Science and Technology
IRB Approval Date
2013-04-16
IRB Approval Number
No. 18/09-12
IRB Name
University of Michigan
IRB Approval Date
2013-03-05
IRB Approval Number
HUM00067957
Post-Trial
Post Trial Information
Study Withdrawal
Intervention
Is the intervention completed?
No
Is data collection complete?
Data Publication
Data Publication
Is public data available?
No
Program Files
Program Files
Reports and Papers
Preliminary Reports
Relevant Papers